|
Patent landscape, scope, and claims: |
Patent 8,883,805 (US 8,883,805): Scope, claim architecture, and US patent landscape analysis
Executive summary
- US 8,883,805 is a small-molecule, structure-claim patent centered on “formula (II)” compounds defined by three substitution handles R1 (aryl/heteroaryl-methyl), R2 (alkyl/aryl), and R3 (substituted alkyl chain/benzyl halogenated/cyano variants), plus product-by-process/compound-preparation and medicament claims.
- The claim set is not limited to a single endpoint compound; it is written as a broad Markush-style genus over multiple heteroaryl-methyl R1 options, multiple Ra halogen/CN/C1-C2 substituents on the aromatic ring, multiple R2 alkyl/cycloalkyl/phenyl choices, and a defined set of R3 substituents (including 2-butyn-1-yl, 2-fluorobenzyl/2-chlorobenzyl/2-bromobenzyl/2-cyanobenzyl and substituted butenyl variants).
- Dependent claims progressively narrow to specific R1/R2/R3 combinations, culminating in a concretely defined compound (dependent claim 6) and manufacturing steps involving phthalyl deprotection (claims 7-12), then medicament (claims 13-14).
- The enforceable scope in the US turns on (1) whether accused products fall within the formula (II) boundaries and (2) for method/product-by-process theories, whether the accused manufacturing matches the phthalyl detachment / solvent / crystallization specifics claimed.
What does US 8,883,805 claim: formula (II) compounds, substituent handles, and Markush boundaries?
Short answer: US 8,883,805 claims a genus of compounds defined by a three-part substitution system (R1, R2, R3) under “formula (II),” then includes process claims for deprotecting phthalyl-protected intermediates to reach the defined compounds, and medicament claims using the resulting compound.
Claim 1: genus of formula (II) compounds
Independent claim 1 recites:
- A compound of formula (II) or an enantiomer thereof
- R1 equals one of a defined set of aryl/heteroaryl-methyl substituents, where:
- The aromatic/heteroaromatic moiety is mono- or disubstituted by Ra
- Ra is limited to a list:
H, F, Cl, Br, CN, CH3, CF3, Et, Ph, OCH3, difluoromethoxy, trifluoromethoxy, or ethoxy
- Special option for adjacent-carbon bonding: —O—CH2—O— or —O—CH2—CH2—O—
- R2 equals Me, Et, propyl, isopropyl, cyclopropyl, or phenyl
- R3 equals one of a defined set including:
- 2-buten-1-yl
- 3-methyl-2-buten-1-yl
- 2-butyn-1-yl
- plus a set of benzyl variants:
2-fluorobenzyl, 2-chlorobenzyl, 2-bromobenzyl, 2-iodobenzyl, 2-methylbenzyl, 2-(trifluoromethyl)benzyl, 2-cyanobenzyl
Enantiomer coverage: claim 1 includes “or an enantiomer thereof,” expanding coverage beyond a racemate if stereocenters exist in the framework.
R1: heteroaryl-methyl universe
R1’s aromatic/heteroaryl portion is constrained to specific scaffolds:
- phenylcarbonylmethyl
- benzyl
- naphthylmethyl
- pyridinylmethyl
- pyrimidinyl-methyl
- quinolinylmethyl
- isoquinolinylmethyl
- quinazolinylmethyl
- quinoxalinylmethyl
- naphthyridinylmethyl
- phenanthridinylmethyl
This list is a finite enumerated Markush set, not an open aromatic “any aryl” provision.
Ra: ring substitution list (where the scope grows)
Ra is where the claim breath is. Ra includes:
- Halogens (F/Cl/Br)
- CN
- alkyl/aryl (methyl, ethyl, phenyl)
- C1-CF3 and O-alkyl groups (trifluoromethyl, methoxy, ethoxy)
- fluorinated alkoxy (difluoromethoxy, trifluoromethoxy)
- and an oxygen-bridged option for adjacent carbon bonding (two oxy-alkyl/alkylene-oxy bridges)
That combination means the patent can cover many regio-isomer and substitution variants as long as the aromatic scaffold is in the R1 list and the substitution pattern fits the Ra set.
R3: constrained substituent set
R3 is constrained to a closed set. It includes:
- three carbon-chain variants (butenyl, methyl-substituted butenyl, butynyl)
- benzyl variants with specific ortho substitutions: F/Cl/Br/I, methyl, CF3, CN
In infringement analysis, this is critical: an accused compound with an otherwise similar framework but different R3 chemistry may fall outside claim 1 even if R1 and R2 are within range.
Claim 2-5: stepwise tightening of R1, Ra, R2, R3
Claim 2 narrows claim 1 by limiting Ra and removing some R1 options:
- Ra list is reduced to: H, F, Cl, CN, CH3, ethyl, methoxy, ethoxy
- R1 set removes multiple heteroaryl scaffolds present in claim 1 (e.g., claim 2 includes fewer R1 types; compared to claim 1 it excludes, for example, phenanthridinylmethyl and others not listed in claim 2 text)
- R3 remains the same enumerated set as in claim 1 except it omits iodobenzyl? Claim 2’s text does include 2-iodobenzyl in the R3 list, but the Ra list shrinks.
Claim 3 further narrows the genus:
- R1 constrained to a smaller set including:
- cyanobenzyl
- (cyanopyridinyl)methyl
- quinolinylmethyl, methylquinolinylmethyl variants
- methylisoquinolinylmethyl variants
- quinazolinylmethyl and methylquinazolinylmethyl variants
- quinoxazinylmethyl and methylquinoxalinylmethyl variants
- dimethylquinoxalinylmethyl variants
- naphthyridinylmethyl
- R2 constrained to: methyl, cyclopropyl, phenyl
- R3 constrained to: 2-buten-1-yl, 3-methyl-2-buten-1-yl, 2-butyn-1-yl, 2-chlorobenzyl, 2-bromobenzyl, 2-cyanobenzyl (notably excludes 2-fluorobenzyl and 2-iodobenzyl in claim 3’s R3 list)
Claim 4 and 5 narrow to specific enumerated triples, with:
- Claim 4: R1 is limited to:
(4-methylquinazolin-2-yl)methyl, (3-methylisoquinolin-1-yl)methyl, or (3-cyanopyridin-2-yl)methyl
R2 = methyl
R3 = 2-butyn-1-yl
- Claim 5: recites that same limitation, essentially making claim 4’s narrowed structure explicit as “of formula wherein …”
Claim 6: the concretized target compound
Claim 6 is the most specific product claim:
- R1 = (4-methylquinazolin-2-yl)methyl or (3-methylisoquinolin-1-yl)methyl or (3-cyanopyridin-2-yl)methyl
- R2 = methyl
- R3 = 2-butyn-1-yl
This positions claim 6 as a final genus-to-definite pivot inside the same structural family.
What does US 8,883,805 cover in method claims: phthalyl deprotection, solvents, and crystallization?
Claims 7-12 switch from product structure to preparation chemistry using a deprotecting step.
Claim 7: deprotecting a phthalyl-protected intermediate
Claim 7 recites a method of preparing a compound of formula (or its physiologically tolerated salt) by:
- Deprotecting a compound of formula (the same R1/R2/R3 set as claim 6),
- where R1 is one of the listed methylquinazolinyl / methylisoquinolinyl / cyanopyridinyl methyl moieties,
- R2 is methyl
- R3 is 2-butyn-1-yl
The key element is the intermediate being protected by a phthalyl protecting group (made explicit in dependent claim 8).
Claim 8: phthalyl detachment
Claim 8 narrows to:
- detaching the phthalyl protecting group.
This is the chemical core of the process claims.
Claims 9-12: reaction medium and crystallization conditions
- Claim 9: phthalyl detachment in the presence of ethanolamine
- Claim 10: phthalyl detachment in the presence of ethanolamine and toluene or THF/water
- Claims 11-12: crystallizing the deprotected compound from ethanol or methanol (and specifically ethanol in claim 12)
Scope impact for enforcement
- These process claims can be asserted where a party performs the same deprotection and crystallization sequence.
- If an accused manufacturer uses a materially different protecting-group strategy (e.g., different N-protecting group) or uses different bases/solvents/crystallization solvents, the process claims can become harder to map.
What medicament claims exist in US 8,883,805 and how broad are they?
Claim 13-14: medicament composition
- Claim 13: medicament comprising the compound obtained by the method of claim 8 (phthalyl detached)
- Claim 14: medicament comprising the compound obtained by claim 12 (crystallized from ethanol)
These claims are composition-of-matter style medicament claims that tie back to the method outcome. In practice they often act as a bridge between process infringement arguments and formulation/market presence.
How strong is the patent estate implied by US 8,883,805’s claim style?
Given the provided claim text, the patent’s strength profile is:
Strength drivers
- Clear closed-set Markush for R3. That narrows potential non-infringing design-arounds.
- Broad Ra substitution list in claim 1. This expands the number of potential covered variants if the R1 scaffold matches and Ra fits.
- Enantiomer inclusion. If chiral centers are present, coverage extends beyond a single stereochemical form.
- Process claims aligned to a common synthetic step. Phthalyl deprotection with ethanolamine and organic/aqueous solvents is a credible chemical motif.
Weakness or litigation-risk drivers
- R1’s scaffold list is finite. Substituting to a scaffold not enumerated in R1 can be a clean design-around.
- R3’s enumerated list is finite. Any “near neighbor” R3 substituent not listed may escape claim 1 even if the rest matches.
- Method claims depend on specifics. Infringement requires the same process parameters if asserted as method claims rather than product claims.
US patent landscape around 8,883,805: what typically clusters with a US structure-and-process claim like this?
No complete landscape can be produced from the claim text alone. A true landscape requires bibliographic identifiers (publication/app number, priority, assignee, related filings, and whether 8,883,805 issued from a PCT family). Without those identifiers, there is no defensible mapping to:
- related continuations/divisionals,
- copending family members in the US,
- claim-interpreting dependencies from earlier filings,
- or regulatory-linked patents (Orange Book) tied to a specific NDA/BLA.
What can be stated from the claim architecture alone:
- The presence of both genus product claims (1-6) and deprotection process claims (7-12) indicates the applicant likely filed (or plans to file) multiple related US applications around:
- the same compound family
- intermediate / protecting group strategies
- salt forms and formulation-ready solids
- The medicament claims indicate the applicant sought commercially enforceable coverage beyond synthesis.
Key claim-scope “infringement mapping” checklist for US 8,883,805
For product infringement against claim 1 (genus)
An accused compound must match all of the following:
- It fits “formula (II)” with the allowed R1/R2/R3 substitution pattern.
- R1 must be one of the listed aryl/heteroaryl-methyl variants and the aromatic/heteroaromatic ring must have substituents only from Ra (or be unsubstituted) with the optional oxygen-bridge possibility if applicable.
- R2 must be Me/Et/propyl/isopropyl/cyclopropyl/phenyl.
- R3 must be one of the listed substituents, including the specific benzyl ortho-substitution set.
For claim 6 (narrow product)
Accused product must have:
- R2 = methyl
- R3 = 2-butyn-1-yl
- R1 limited to the listed methylquinazolinyl / methylisoquinolinyl / cyanopyridinyl methyl options.
For method infringement (claims 7-12)
Accused manufacturer must perform:
- a phthalyl deprotection step of the specific protected intermediate(s),
- using ethanolamine and, in some claim versions, toluene or THF/water,
- followed by crystallization from ethanol or methanol (and specifically ethanol for claim 12).
Key Takeaways
- US 8,883,805 is a structured small-molecule claim set built around a formula (II) Markush-style genus with tight enumerations for R1 scaffolds, Ra substituents (claim 1), R2 substituents, and R3 substituents.
- Claims 4-6 narrow to specific substitution triples anchored by R2=methyl and R3=2-butyn-1-yl, with a limited set of R1 heteroaryl-methyl groups.
- Claims 7-12 add enforceability through a specific synthesis route: phthalyl deprotection of the protected intermediate, with ethanolamine and optional solvent/crystallization parameters.
- Without additional bibliographic data (assignee, priority, publication/application number, and related family members), the broader US patent landscape cannot be reliably enumerated, including related continuations, method variants, and Orange Book-linked patents.
FAQs
1) What is the most limiting element across US 8,883,805 claim 1?
R3 is the most constraining because it is an enumerated closed set of substituents (alkenyl/alkynyl and specific ortho-substituted benzyl variants).
2) Do US 8,883,805 claims cover enantiomers?
Yes. Claim 1 covers “the compound … or an enantiomer thereof.”
3) Can a manufacturer avoid infringement by changing R2 to a different alkyl?
Changing R2 to anything outside the enumerated set (Me/Et/propyl/isopropyl/cyclopropyl/phenyl) would fall outside claim 1’s R2 definition.
4) What does US 8,883,805 require for process infringement?
For claims 7-12, infringement requires performing the claimed phthalyl deprotection step and, depending on the claim asserted, using ethanolamine with specified solvents and crystallizing from ethanol/methanol.
5) Are medicament claims limited to a particular formulation?
The medicament claims are composition-style but are tied to the compound “obtained by” the claimed deprotection/crystallization method; no additional formulation excipients are specified beyond “inert carriers and/or diluents.”
References
No references are provided because only claim text was supplied and no patent bibliographic record or external sources were provided for citation.
More… ↓
⤷ Start Trial
|
